


MEDICINAL PRODUCTS 2019

ImmuCell

IMMUCELL CORP DE Rank 15 of 50





MEDICINAL PRODUCTS 2019

ImmuCell

IMMUCELL CORP DE Rank 15 of 50

The relative strengths and weaknesses of IMMUCELL CORP DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IMMUCELL CORP DE compared to the market average is the variable Property, Plant and Equipment, Net, increasing the Economic Capital Ratio by 94% points. The greatest weakness of IMMUCELL CORP DE is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 74%, being 80% points above the market average of -5.9%.

Input Variable	Value in 1000 USD
Assets, Current	6,421
Assets, Non-Current	13
General and Administrative Expense	9,616
Goodwill	229
Liabilities, Current	2,565
Liabilities, Non-Current	8,421
Other Assets	40
Other Compr. Net Income	31
Other Expenses	175
Other Liabilities	0
Other Net Income	0
Other Revenues	10,986
Property, Plant and Equipment, Net	26,028
Research and Development	3,517

Output Variable	Value in 1000 USD
Liabilities	10,986
Assets	32,731
Expenses	13,308
Revenues	10,986
Stockholders Equity	21,744
Net Income	-2,322
Comprehensive Net Income	-2,306
Economic Capital Ratio	74%

